AI-generated · cited to primary sources · not investment advice · How we research
Sai Life
Our verdict on Sai Life isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The company achieved an EBITDA margin of 34% in Q3 FY26 and 30% for 9M FY26, reaching the upper end of their long-term goal ahead of schedule. (4 exceeded, 1 met across 5 tracked commitments)
“Invested ₹405 Cr as on date in capital expenditure, against a plan of ₹700 Cr for FY26”
The expansion to 1,150 KL is underway with specific blocks (PB 14 & 15) scheduled for 2026 completion. (1 in progress across 1 tracked commitment)
“These strategic investments will nearly double Sai’s overall manufacturing capacity by FY27, while diversifying its footprint and reducing concentration risk”
See the full cited Management analysis of Sai Life
How durable is the business?
The CDMO segment is expanding rapidly, with revenue more than doubling year-on-year, driven by deeper engagement with global clients and increased manufacturing capacity. (5 expanding)
“CDMO recorded revenues of ₹314 Cr in Q1FY26, up 113% from ₹148 Cr in Q1FY25”
The moat is strengthening as the company doubles its Process R&D capacity and expands into new modalities like peptides and ADCs, deepening the 'integrated' nature of their client partnerships. (2 expanding)
“No, actually, research is doubling. And we are adding, obviously, formulation services, early phase formulation, peptide capability in the research building... that forward-looking approach has given us that little bit of an edge.”
See the full cited Business Model analysis of Sai Life
Where does growth come from?
The company is aggressively accelerating its capital expenditure, investing ₹134 Cr in Q1FY26 alone with a planned annual spend of ~₹700 Cr for FY26 to nearly double manufacturing capacity by FY27. (5 accelerating across 5 signals, 3 leading indicators)
“Positioned to achieve 15-20% revenue CAGR over 3-5 years* & 28-30% EBITDA margins in the next 2-3 years*”
CDMO revenue growth is accelerating significantly, jumping from 33% YoY in previous periods to 113% YoY in the current quarter. (5 accelerating across 5 signals)
“CDMO recorded revenues of ₹1,417 Cr in FY26, up 33% from ₹1068 Cr in FY25”
See the full cited Future Growth analysis of Sai Life
What could break the thesis?
Execution risk is intensifying as the company has multiple large-scale projects running simultaneously, including a new 200 KL capacity at Bidar and a new Process R&D Block in Hyderabad. Managing the 'onboarding of 253 scientists' and technical staff while commissioning these sites increases the complexity of execution. (5 intensifying, 2 high-severity)
“For fiscal '27, we expect capex in the range of INR1,100 crores to 1,300 crores... We expect to fund the capex through a mix of internal accruals and debt.”
This risk is emerging as a more concrete concern due to geopolitical discussions regarding 'most favored nation' policies and US reshoring. However, management believes R&D will remain in Asia and the impact on intermediates will be minimal. (1 emerging, 2 easing, 1 intensifying)
“it's almost impossible right now to figure out the geopolitical angle... the geographies we supply to might change and how tariff is affected.”
See the full cited Risk analysis of Sai Life
Read the full thesis on Sai Life
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.